Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2021, specifically dated December 7, 2021. The filing serves to incorporate a press release regarding the status of the company's Phase III clinical study for psoriasis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical trial milestones rather than financial performance.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary update concerns the operational timeline of the Phase III Psoriasis Study.
Outlook, Management Commentary, and Risks
- Clinical Trial Status: The Phase III Psoriasis Study is scheduled to complete the 16-week treatment of the last patient in January 2022.
- Data Release: Topline data from the study is expected in the first quarter of 2022.
- Regulatory Context: The press release is incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the actual completion date of the 16-week treatment for the last patient in January 2022.
- Monitor the release of topline data in Q1 2022 for efficacy and safety results.
- Review the full text of the attached press release (Exhibit 99.1) for any additional details on study design or patient enrollment.